- Home
- FORA vs ETON Comparison
FORA vs ETON Comparison
Compare FORA & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- ETON
- Stock Information
- Founded
- FORA 2014
- ETON 2017
- Country
- FORA United States
- ETON United States
- Employees
- FORA N/A
- ETON N/A
- Industry
- FORA Computer Software: Prepackaged Software
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- ETON Health Care
- Exchange
- FORA Nasdaq
- ETON Nasdaq
- Market Cap
- FORA 63.8M
- ETON 199.5M
- IPO Year
- FORA N/A
- ETON 2018
- Fundamental
- Price
- FORA $2.10
- ETON $8.77
- Analyst Decision
- FORA Strong Buy
- ETON Strong Buy
- Analyst Count
- FORA 1
- ETON 3
- Target Price
- FORA $5.00
- ETON $12.00
- AVG Volume (30 Days)
- FORA 14.2K
- ETON 214.1K
- Earning Date
- FORA 11-07-2024
- ETON 11-11-2024
- Dividend Yield
- FORA N/A
- ETON N/A
- EPS Growth
- FORA N/A
- ETON N/A
- EPS
- FORA 0.06
- ETON N/A
- Revenue
- FORA $20,371,880.00
- ETON $31,381,000.00
- Revenue This Year
- FORA N/A
- ETON $19.61
- Revenue Next Year
- FORA $10.64
- ETON $35.39
- P/E Ratio
- FORA $36.34
- ETON N/A
- Revenue Growth
- FORA 6.97
- ETON 8.14
- 52 Week Low
- FORA $2.00
- ETON $3.03
- 52 Week High
- FORA $4.15
- ETON $8.66
- Technical
- Relative Strength Index (RSI)
- FORA 38.13
- ETON 76.07
- Support Level
- FORA $2.05
- ETON $7.58
- Resistance Level
- FORA $2.16
- ETON $8.66
- Average True Range (ATR)
- FORA 0.05
- ETON 0.42
- MACD
- FORA 0.00
- ETON -0.07
- Stochastic Oscillator
- FORA 31.77
- ETON 91.49
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.